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Purpose: This treatment planning study was conducted to determine whether spot scanning proton beam
therapy (SSPT) reduces the risk of grade P3 hematologic toxicity (HT3+) compared with intensity mod-
ulated radiation therapy (IMRT) for postoperative whole pelvic radiation therapy (WPRT).
Methods and materials: The normal tissue complication probability (NTCP) of the risk of HT3+ was used as
an in silico surrogate marker in this analysis. IMRT and SSPT plans were created for 13 gynecologic malig-
nancy patients who had received hysterectomies. The IMRT plans were generated using the 7-fields step
and shoot technique. The SSPT plans were generated using anterior-posterior field with single field
optimization. Using the relative biological effectives (RBE) value of 1.0 for IMRT and 1.1 for SSPT, the
prescribed dose was 45 Gy(RBE) in 1.8 Gy(RBE) per fractions for 95% of the planning target volume
(PTV). The homogeneity index (HI) and the conformity index (CI) of the PTV were also compared.
Results: The bone marrow (BM) and femoral head doses using SSPT were significantly lower than with
IMRT. The NTCP modeling analysis showed that the risk of HT3+ using SSPT was significantly lower than
with IMRT (NTCP = 0.04 ± 0.01 and 0.19 ± 0.03, p = 0.0002, respectively). There were no significant differ-
ences in the CI and HI of the PTV between IMRT and SSPT (CI = 0.97 ± 0.01 and 0.96 ± 0.02, p = 0.3177, and
HI = 1.24 ± 0.11 and 1.27 ± 0.05, p = 0.8473, respectively).
Conclusion: The SSPT achieves significant reductions in the dose to BMwithout compromising target cov-
erage, compared with IMRT. The NTCP value for HT3+ in SSPT was significantly lower than in IMRT.
 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Whole pelvic radiation therapy (WPRT) plays an important role
in the treatment of gynecologic cancers, especially cervical andendometrial cancers. Conventional WPRT contains approximately
40% of the total body bone marrow (BM) and results in hemato-
logic toxicity (HT) [1]. Concurrent chemoradiotherapy (CCRT) is
used to improve treatment outcome. However, adding chemother-
apy increases the risk of severe HT. Severe HT is critical issue
because it disturbs the execution of treatment on schedule such
as interruptions of radiotherapy and holds or stops chemotherapy
[2].
There are many studies that evaluate the relationship between
the dosimetric parameter of BM and the severity of HT. Mell et al.
have shown that a low dose irradiation volume of BM such as V10Gy
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cervical patients [1].
Recent advances in radiotherapy provide us with the superior
conformal dose distribution, intensity modulated radiotherapy
(IMRT) where photons enable a highly conformal dose distribution
to targets. Several studies have demonstrated the utility of IMRT
for WPRT. Dosimetric studies have shown that IMRT could reduce
the irradiated volume of the BM compared with conventional
treatment planning and clinical studies have suggested that IMRT
reduced acute HT compared with conventional radiation therapy
[3]. It has been proven that the reduction enabled by the low dose
to the BM leads to reductions in the risk of severe HT [4].
Proton beam therapy (PBT) has a distinct physical characteris-
tics known as the Bragg Peak, and PBT has been used to spare
the normal tissue. Among several treatment delivery systems of
PBT, the recent spot-scanning proton beam therapy (SSPT) system
can provide a large treatment field (30 cm  40 cm) which can
cover the whole pelvic region with one scanning field and enables
delivery of a complex dose distribution [5,6]. Therefore, we
hypothesized that SSPT could reduce the low dose to BM in WPRT
compared with IMRT. A dosimetric comparison study has shown
that intensity modulated proton beam therapy (IMPT) using SSPT
was useful in sparing of pelvic BM, small bowel, rectum, and
bladder compared with IMRT [7,8]. With IMPT it is possible to pro-
duce more complex dose distributions than SSPT with single field
optimization (SFO), however IMPT is more susceptible to set up
and range uncertainties than SFO [9,10]. When conducting clinical
trials after an in silico study, it is preferable that SFO is selected as it
is more robust than IMPT, and for this reason we decided to use
SFO rather than IMPT. Moreover, SSPT using SFO has not been com-
pared with IMRT yet. So, we do not know whether SSPT offers
advantages compared to IMRT even without intensity modulation
to reduce the dose to these organs. The first purpose of this study
is to investigate whether SSPT using SFO reduces the dose to BM
compared with IMRT for the organs at risk (OARs).
Also, to the best of our knowledge, the hypothesis of whether
the reduction of the dose to BM by SSPT would result in risks of
HT has not been evaluated in prospective clinical studies nor in
simulation studies based on dosimetric results. Bazan et al. have
suggested that the Lyman-Kutcher-Burman normal tissue compli-
cation probability (LKB-NTCP) based on dose volume statistics is
useful as an in silico surrogate endpoint to estimate the risk of
HT in patients who receive pelvic radiotherapy with chemotherapy
[11,12]. To verify this, we have also investigated whether the
reduction of the dose to BM by SSPT would result in the risk of
HT comparing to IMRT using the LKB-NTCP model in this study.
The number of PBT facilities is increasing but the number of
patients who can receive PBT is still limited. Therefore, it is neces-
sary to be selective in determining who should benefit from PBT,
before conducting clinical studies. The aim of this in silico study
is to compare the dose of PBT to IMRT, and to evaluate the risk
of adverse effects.2. Methods and materials
2.1. Patients
This dosimetric study consists of 13 patients who had previ-
ously received radiotherapy to the pelvic region for adjuvant treat-
ment or recurrent diseases in gynecological malignancies (cervical
cancer; n = 8, uterine body cancer; n = 4, and ovarian cancer; n = 1)
at our institution from 2008 to 2014. All of them had received
hysterectomy (with or without pelvic lymph node dissection).
We created all plans anew based upon the virtual necessity of
post-operative WPRT. This makes it possible to disregard the actualdiagnoses or conditions of the patients. This study has been
approved by the ethics committee of our hospital (014-0055).
2.2. Contouring
All patients received a planning computed tomography (CT) at a
slice thickness of 2 or 2.5 mm. The clinical target volume (CTV) was
contoured on individual axial CT slices, according to the consensus
guidelines for postoperative treatment of endometrial and cervical
cancer [13]. The CTV included the common, external, and internal
iliac lymph node regions, the upper vagina, parametrial and par-
avaginal soft tissue, and presacral lymph nodes. The planning tar-
get volume (PTV) was created by expanding the CTV with a 5 mm
margin.
The bladder, rectum, bowel bag, femoral heads, and BM were
contoured as the OARs according to the normal tissue contouring
guidelines [14]. The bowel bag was contoured inferiorly above
the rectum including both the small and large bowel and bowel
loop, superiorly 2 cm above the PTV. The BM including the ilium,
lower pelvis, and lumbosacral spine were contoured 2 cm supe-
rior/inferior to the PTV. All structures were contoured using the
Pinnacle3 treatment planning system (TPS) (ver.9.0; Philips, Inc.,
Madison, WI).
2.3. Planning methods
The IMRT plans were generated using Pinnacle3 TPS assuming
photon treatment with an Clinac CL-iX (Varian Medical Systems,
Palo Alto, CA) LINAC. We used seven evenly spaced intensity mod-
ulated fields which were generated with a 6 MV photon beam with
a step and shoot multi leaf collimator technique.
The SSPT plans were calculated on the VQA TPS (Hitachi, Ltd.,
Hitachi, Japan), assuming proton treatment with a proton beam
therapy system, PROBEAT-RT (Hitachi Co Ltd, Hitachi, Japan) [15].
Targets and normal structures were imported from Pinnacle3 TPS
to VQA TPS via DICOM-RT. The SSPT plans consisted of an
anterior-posterior (A-P) direction beam with the SFO method, in
which each beam is optimized to deliver a uniform dose distribu-
tion to the target without intensity modulation [16], and not the
multiple field optimization (MFO) method which is required for
IMPT. There are several beam angles to choose for treatment of
whole pelvic region in proton therapy. Lin et al. used the posterior
oblique field technique [17] and Marnitz et al. used the three field
technique (two oblique anterior beam and one posterior) [8]. We
selected the AP-PA approach considering that we would be able
to avoid differences in beam angles of individual patient which
could affect the results.
Ninety-four energies between 70.2 and 220.0 MeV are available
for SSPT in our facility. The full width at half maximum (FWHM) of
the spot size in air at the isocenter varies from 6.8 mm at
220.0 MeV to 18.3 mm at 70.2 MeV, and the ellipticity of the beam
is close to zero. The spot spacings in the horizontal and vertical
directions are both determined automatically in the TPS, and dis-
tributed from 4.8 to 5.6 mm in this study.
The distal margin (DM), proximal margin (PM), and lateral mar-
gin (LM) were beam specific margins for the expansion from the
CTV as an optimization volume for SSPT [16,18]. To account for
the range uncertainty, the DM and PM were used as in the follow-
ing equation,
DM; PM ¼ 0:035 Rþ 0:1 cm ð1Þ
where R stands for the depth of the distal and proximal edges in
water equivalent space and 0.1 cm is the direction of the proton
delivery for the beam uncertainties [16]. The values of DM and
PM for WPRT patients were 6.0–9.0 mm and 2.0–4.0 mm, respec-
tively. The target volume must be expanded laterally from the
Table 1
Summary of the results of the DVHs analysis for the PTV and organs at risk.
Organ Parameter Objectives IMRT SSPT P value
PTV D93% [%] >99 [%] 99.91 ± 0.15 100.00 ± 0.01 0.0352
D95% [%] >95 [%] 95.17 ± 0.20 95.25 ± 0.21 0.3101
D110% [%] <10 [%] 0.39 ± 1.01 0.66 ± 0.76 0.1855
CI 0.97 ± 0.01 0.96 ± 0.02 0.3177
HI 1.24 ± 0.11 1.27 ± 0.05 0.8473
Bone marrow V10Gy [%] <90 [%] 83.47 ± 2.30 55.14 ± 3.00 0.0002
V20Gy [%] <75 [%] 64.86 ± 3.18 42.63 ± 5.20 0.0002
Rectum Max dose [cGy] 4756.43 ± 107.80 4749.34 ± 101.54 0.4730
V40Gy [%] <60 [%] 53.34 ± 5.79 50.68 ± 15.28 0.1219
Bladder Max dose [cGy] 4768.18 ± 105.55 4845.83 ± 93.84 0.0133
V45Gy [%] <35 [%] 23.35 ± 11.01 26.16 ± 13.13 0.1367
Bowel bag Max dose [cGy] 4875.67 ± 112.70 4965.82 ± 81.47 0.0009
V40Gy [%] <30 [%] 25.81 ± 4.19 24.61 ± 4.92 0.1082
Femoral heads V30Gy [%] <15 [%] 7.28 ± 4.53 2.09 ± 2.34 0.0002
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sidering internal target motion and setup errors [18]. With this, the
LM including the internal margin and set-up margin can be calcu-
lated by a summation of these two factors as follows,
LM ¼ 0:04 Sþ 0:3 cm ð2Þ
where S is the maximum size of the CTV, as uncertainties in target
localization are considered to increase with increases in the target
size. The values of LM for WPRT patients were 8.5–11.5 mm.
In this article, the dose unit of Gray (Gy) represents the dose
weighted by the relative biological effectives (RBE). An RBE value
of 1.0 was employed for the photon IMRT and 1.1 for SSPT plans.
The prescribed dose was 45 Gy in 25 fractions. All plans were
designed so that 95% of the PTV received the prescription dose,
at least 99% of the PTV received 93% of the prescribed dose and
no more than 10% of the PTV received 110% of the prescribed dose.
The dose constrains for the BM were defined as V10Gy < 90% and
V20Gy < 75%, as previous studies have shown that V10Gy or V20Gy is
associated with severe HT [1]. For other OARs, the following con-
strains were used: rectum V40Gy < 60%, bladder V45Gy < 35%, bowel
bag V40Gy < 30%, femoral heads V30Gy < 15% and the maximum dose
to the rectum, bladders and bowel bag should not exceed 50 Gy,
the dose constraints for the PTV and OARs are summarized in
Table 1 [19]. A plan was considered acceptable when it met at least
the prescribed dose to the PTV and the maximum dose to the OARs.
2.4. Evaluation
The dose volume histograms (DVHs) were generated for the PTV
and all OARs. The V10Gy and V20Gy of the BM were calculated and
compared to evaluate the risk of severe HT. The different levels
of irradiated volumes of other OARs: V45Gy of the bladder, V40Gy
of the rectum and bowel bag, and V30Gy of the femoral heads were
also calculated and evaluated.
To compare target conformity and heterogeneity, the confor-
mity index (CI) and homogeneity index (HI) of PTV were calculated
for the IMRT and SSPT plans. There are various definitions of CI and
HI in previous studies [20], and here we used the following
formulas: CI = Vp/VPTV where Vp is the target volume enclosed by
the prescribed dose line, and VPTV is the volume of the PTV;
HI = Dmax/Dmin where Dmin and Dmax were the minimum and
maximum doses of the PTV. These analyses were performed with
non-shifted plans without modification of the CT values, namely
those of the nominal plan.
Two different approaches were employed in the evaluation of
the robustness of the target coverage and the representative OARs.
The uncertainties related to patient positioning were evaluated by
six different plans with a ±5 mm (left-right (L-R), anterior-posterior (A-P) and superior-inferior (S-I)) isocenter shift on the
planning CT (shifted plan) [17,21]. The effect of interfractional
anatomical changes such as emptying or filling of air cavities was
evaluated by a plan termed HU (HU plan), generated by re-
calculating with the Hounsfield Units of the bowel bag as 20HU,
which was the mean value of several areas neighboring the bowel
tissue in the bowel bag. The DVHs were generated for CTV and the
OARs in all shifted and HU plans to evaluate the robustness.
2.5. Lyman-Kutcher-Burman–normal tissue complication probability
(LKB-NTCP) model and gEUD
As the in silico surrogate for the risk of HT we used the
LKB-NTCP model [22–24] with Bazan’s methods [11,12]. The
LKB-NTCP model is used to estimate the complication probabilities
for nonuniformaly irradiated tissue based on DVHs. The
Lyman-NTCP [22] describes the probability of complications for a
uniform dose, D, to the organ as
NTCP ¼ uðtÞ ¼ 1ﬃﬃﬃﬃﬃﬃ
2p
p
Z t
1
exp  x
2
2
 
dx ð3Þ
t ¼ D TD50
m  TD50 ð4Þ
TD50ðvÞ ¼ TD50ð1Þ  vn ð5Þ
v ¼ V
Vref
ð6Þ
These equations have 4 parameters, TD50, m, n, and Vref. The
TD50 value is the tolerance dose for a 50% complication probability
for uniform doses to the organ; m is a dimensionless parameter to
determine the slope of the complication probability according to
dose curve, and n is the parameter for the volume dependence of
the complication probability, finally Vref is a reference volume for
the OARs [25]. TD50(1) is the tolerance dose of the whole organ
irradiation.
For the uniform dose D in Eq. (4), we used the generalized
equivalent uniform dose (gEUD) [26,27]. Here, the gEUD was calcu-
lated as
gEUD ¼
Xk
i¼1
v idai
 !1=a
ð7Þ
where a is a parameter equal to 1/n, which parameter n is the vol-
ume dependence of the complication probability [25], and k repre-
sents unequal fractional sub-volumes. The di term is the dose for
each bin in a differential DVHs, and vi is the volume in a specific
Fig. 1. Images showing the IMRT and SSPT dose distributions for a representative case. Dose distributions for IMRT (above) and SSPT (below) are shown. IMRT: intensity
modulated radiation therapy, SSPT: spot scanning proton therapy.
Fig. 2. Boxplots of the IMRT (white) and SSPT (gray) of CI and HI for the PTV. IMRT:
intensity modulated radiation therapy, SSPT: spot scanning proton therapy, PTV:
planning target volume, CI: conformity index, HI: homogeneity index.
Fig. 3. Dose volume histograms (DVHs) for the bone marrow (BM). The solid and
dot line represents the average dose volume histogram of the 13 patients for IMRT
(line) and SSPT (dot line), respectively, while the surrounding shading represents
the range for the 13 patients. In the SSPT plan, we were able to reduce the low dose
region of the BM below that of the IMRT plan.
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same NTCP as the original inhomogeneous dose distribution.
Bazan et al. analyzed the relationship between dose volume
data and the incidence of HT in 32 patients receiving CCRT for
gynecological malignancies [12]. There they applied the LKB-
NTCP model for the dose-response curve of HT equal to or higher
than Grade3 (HT3+) according to the Common Terminology Crite-
ria for Adverse Events ver.4.0 [28] and found the parameters n = 1,
m = 0.27, and TD50 = 35 Gy in Eqs. (4) and (5) [12].2.6. Statistical analysis
The CI and the HI of the PTV, DVHs of the PTV and each OARs,
gEUD for BM, and NTCP value for HT3+ were compared for the
IMRT and SSPT. The Wilcoxon signed rank test was used for all sta-
tistical comparisons. A p value of <0.05 was considered statistically
significant. All statistical analyses were performed by JMP Pro 11
(SAS Institute Inc., Cary, NC, USA).3. Results
3.1. DVHs analysis
Twenty-six plans were generated (13 IMRT plans and 13 SSPT
plans), with plan comparisons shown in Fig. 1. All plans achievedthe prescribed dose to the PTV maintaining doses for the OARs
below their respective dose constrains.
There were no statistically significant differences in CI or HI of
PTV between the IMRT and SSPT plans (CI = 0.97 ± 0.01 for IMRT
and 0.96 ± 0.02 for SSPT, HI = 1.24 ± 0.11 for IMRT and 1.27 ± 0.05
for SSPT and p = 0.3177, 0.8473, respectively) (Fig. 2).
The volumes of BM receiving 10 and 20 Gy using SSPT were sig-
nificantly lower than with IMRT (V10Gy = 83.47 ± 2.30% for IMRT
and 55.14 ± 3.00% for SSPT, V20Gy = 64.86 ± 3.18% for IMRT and
42.63 ± 5.20% for SSPT and p = 0.0002, 0.0002, respectively). Fig. 3
plots the DVHs data for BM, showing that the SSPT demonstrated
lower irradiated volumes below 30 Gy for BM.
The SSPT also decreased the V30Gy of the femoral heads
(7.28 ± 4.53% for IMRT and 2.09 ± 2.34% for SSPT, and p = 0.0002).
On the other hand, there were no significant differences between
IMRT and SSPT for the V45Gy of the bladder, and the V40Gy of the
rectum and bowel bag. The DVHs for the femoral heads, rectum,
bladder, and bowel bag are shown in Fig. 4. Table 1 shows a
detailed summary of DVHs results for the PTV and the OARs.
The results of the evaluation of the robustness for target cover-
age are detailed in Table 2. For the CTV D98, the dose received by
98% of the volume of the CTV, was measured in each shifted plan.
Changes in the mean value of CTV D98 of the shifted plans for the
13 patients were within 1% in both IMRT and SSPT (left: 0.6% for
Fig. 4. An example dose volume histograms of OARs Plots of dose volumes with IMRT (line) and SSPT (dot line) of the DVHs for a) the femoral heads, b) bowel bag, c) rectum,
and d) bladder.
Table 2
Mean and standard deviations of CTV D98 in the 13 patients for the nominal plan, the
HU plan, and the plans shifted 5 mm along each axis.
IMRT [cGy] SSPT [cGy]
Nominal 4580.77 ± 36.62 4517.75 ± 69.06
HU 4544.62 ± 38.43 4472.14 ± 205.98
Left 4551.54 ± 24.44 4496.69 ± 44.85
Right 4555.38 ± 20.66 4520.36 ± 67.49
Anterior 4546.92 ± 40.90 4514.16 ± 70.77
Posterior 4539.23 ± 32.78 4493.40 ± 48.66
Superior 4543.08 ± 52.66 4489.11 ± 55.78
Inferior 4554.62 ± 38.65 4499.21 ± 53.57
Abbreviations: CTV D98: the dose received by 98% of the volume of the CTV,
Nominal: nominal plan, HU: plan in which the value of the Hounsfield Units in the
bowel bag was replaced by 20HU, Left: plan shifted 5 mm to the left, Right: plan
shifted 5 mm to the right, Anterior: plan shifted 5 mm to the anterior, Posterior:
plan shifted 5 mm to the posterior, Superior: plan shifted 5 mm to the superior,
Inferior: plan shifted 5 mm to the inferior directions respectively.
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and 0.1%, posterior: 0.9% and 0.1%, superior: 0.8% and 0.6%,
inferior: 0.6% and 0.4%, respectively). The changes in the mean
values of CTV D98 of HU plans were 0.8% in IMRT and 1.0% in
SSPT. The largest change of HU plan reached 14.3% in SSPT,
whereas the changes were within 3% in all IMRT plans.
We evaluated the robustness for the representative OARs, BM,
and femoral heads, in which significant differences between IMRT
and SSPT were observed in the dose volume analysis using the
nominal plan as mentioned above; the V10Gy and V20Gy of BM,
and V30Gy of femoral heads were calculated in each shifted plan.
The changes in the mean value of BM V10Gy and V20Gy of the
shifted plans for the 13 patients were within 1% in both IMRTand SSPT (V10Gy; left: 0.0% for IMRT and 0.6% for SSPT, right:
0.1% and 0.2%, anterior: 0.7% and 0.2%, posterior: 0.7% and
0.2%, superior:1.0% and0.8%, inferior: 0.7% and 0.1%. V20Gy; left:
0.4% and 0.3%, right: 0.0% and 0.2%, anterior: 0.4% and 0.2%,
posterior: 0.0% and 0.2%, superior: 0.8% and 0.0%, inferior: 0.5%
and 0.8%, respectively). The changes in the mean values of V10Gy
and V20Gy for the BM of HU plans were within 3% (V10Gy; 0.0% for
IMRT and 0.3% for SSPT. V20Gy; 0.3% and 2.3%, respectively).
In one case the changes in the V20Gy of the HU plan was 11.7%
in SSPT. Fig. 5 plots the DVHs data for the BM of the plan robust-
ness (Fig. 5(a) for the shifted plans and Fig. 5(b) for the HU plans),
which show that the SSPT demonstrated a lower irradiated volume
below 30 Gy as with the nominal plan (shown in Fig. 3).
The changes in the mean value of the femoral head V30Gy of the
shifted plans for the 13 patients were from 39.6% to 59.5% in
IMRT and from 78.1% to 380.9% in SSPT. The changes in the mean
value V30Gy for the femoral heads of HU plans were within 0.5%
(0.1% for IMRT and 0.3% for SSPT). All femoral heads V30Gy of
the shifted plans and the HU plans were below 9% in SSPT. The
V30Gy was exceeded 15% in two cases of IMRT. The V30Gy of SSPT
was significantly smaller than with IMRT in both the shifted and
HU plans (p = left: 0.0002, right: 0.0002, anterior: 0.0002,
posterior: 0.0002, superior: 0.0002, inferior: 0.0005 and HU:
0.0002, respectively).3.2. Estimated risk of HT3+
The NTCP values for HT3+ for the IMRT and SSPT plans were
0.19 ± 0.03 and 0.04 ± 0.01, respectively, with the SSPT results
showing statistically significantly lower mean NTCP values than
with IMRT (p = 0.0002). The gEUD of BM for IMRT and SSPT were
Fig. 5. Dose volume histograms (DVHs) for the bone marrow (BM) of the shifted (a) and HU plans (b). The gray and dotted lines represent the average dose volume histogram
of the 13 patients with IMRT and SSPT, respectively for shifted (a) and HU plans (b). The surrounding shading represents the range for the 13 patients.
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the SSPT was statistically significantly below the IMRT gEUD of
BM (p = 0.0002).
We plotted the NTCP value versus gEUD of the BM for the IMRT
and SSPT according to the Bazan method (Fig. 6) [12]. The pre-
dicted NTCP for HT3+ was below 0.05 under 1950 cGy, 0.10 at
2290 cGy, and doubled to 0.20 at 2710 cGy. This shows that the
predicted NTCP value gradually increases above around
2000 cGy. The maximum gEUD for SSPT was 2020 cGy with an
NTCP value of 0.059. The maximum and minimum gEUD for IMRT
were 2663 cGy and 2402 cGy, and the NTCP values here were 0.21
and 0.12.Fig. 6. Layman-Kucher-Burman normal tissue complication probability (LKB-NTCP)
model for grade 3 hematologic toxicity (HT3+) A plot of NTCP values for IMRT ()
and SSPT (s) with the generalized equivalent uniform dose (gEUD). With the SSPT
plan, it was possible to reduce both of the values of NTCP and gEUD below those of
the IMRT plan.4. Discussion
The main objective of this treatment planning study is to inves-
tigate if the risk of HT is reduced using SSPT with SFO compared to
photon IMRT. Previously, there have been a small number of clin-
ical reports of PBT for the treatment of gynecological malignancies
[17,29]. The small number of studies is related to the fact that it
was difficult to generate a large treatment field by passive scatter-
ing PBT systems which had been widely used so far. The present
study showed that SSPT is able to cover the whole of the pelvic
region with one scanning field (30 cm  40 cm) and that this is
useful to reduce the risk of HT when compared with IMRT. In
addition, since the large scanning field makes the irradiation time
longer, scan path optimization is one of the way for cost-effective
treatment delivery [30].
Our results show that SSPT reduced the low dose irradiation
volumes of BM such as the V10Gy and V20Gy. Dinges et al. showed
that IMPT can spare BM compared to IMRT at a wide range of dose
levels, and our results are consistent with those results [7].
However, a difference in the dose volume statistics itself does
not necessarily affect the risk of HT in clinical outcomes. Using
the LKB-NTCP model and parameters in our assumptions, the
present study shows that the NTCP value for HT3+ in SSPT, even
without intensity modulation, was significantly lower than in
IMRT. This indicates that SSPT has a positive impact on clinical out-
comes regarding HT when comparing with IMRT.
Although randomized studies are needed to confirm if PBT
reduces the toxicity comparing to IMRT, it is hard to conduct such
studies. To estimate and evaluate the effectiveness of PBT overphoton therapy, several studies using the NTCP modeling analysis
exist. Jakobi et al. conducted in silico study using NTCP modeling
analysis in head and neck region to identify patients who may ben-
efit from PBT [31–33]. Makishima et al. showed that NTCP value for
the lung and heart decreased in proton plan compared with photon
plan in esophageal cancer [34]. Toramatsu et al. showed that large
size of hepatocellular carcinoma could be more safely treated with
SSPT than IMRT regarding the risk of radiation-induced liver dis-
ease using NTCP modeling analysis [35]. To the best of our knowl-
edge, our study is the first study to evaluate the risk of HT by NTCP
modeling analysis using PBT.
We also compared the DVHs data of other OARs. Here the SSPT
decreased the dose to the femoral heads compared to IMRT (statis-
tically significantly), but there were no significant differences in
the doses to the bowel bag, the bladder, or rectum. There are two
possible reasons why our results are different from previous stud-
ies. Marnitz et al. showed that, compared to IMRT, IMPT using
three fields (two oblique anterior beams and one posterior)
reduced the dose to the bowel bag and rectum significantly [8].
Here we used AP-PA fields with SFO, and differences in the beam
angle and optimization methods could have affected the results.
More work is required to conclude whether the dose reduction
could result in lower NTCP with these OARs.
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as set-up error, range uncertainty, imaging uncertainty, and others
is the issue to be solved in IMPT [9,10]. To consider these uncer-
tainties, robustness optimization was being developed and it was
available only a limited TPS [36]. Since TPS and quality assurance
procedures are progressively improving, MFO would be the sensi-
ble choice in the WPRT.
We confirmed that the CI and HI for the PTV were comparable in
SSPT and IMRT in the study here. These results indicate that SSPT
can achieve reductions in doses to the BM without sacrificing the
dose coverage of the PTV. Marnitz et al. have shown that the CI
and HI for the target were similar in a dosimetric study to compare
IMRT, helical tomotherapy, volumetric arc therapy (VMAT), and
IMPT for twenty patients suffering from cervical cancer [8]. Our
results are consistent with the Marnitz results.
One critical issue of SSPT is the effect of uncertainties related to
the set-up and interfractional anatomical changes. Differences of
D98 for CTV between the nominal and shifted plans were within
1% in SSPT. However, there was a large difference, more than
10%, between the nominal and HU plan in one case in SSPT. This
may indicate that the robustness of SSPT is inferior to IMRT in
some cases.
The average changes of V20Gy for the BM of the HU plan were
2.3% in SSPT, and in one case the change in V20Gy of the HU plan
was 11.7%. All values of the V20Gy and V10Gy for the BM of the HU
plans were smaller than nominal, so the risk of HT would not be
larger than the nominal value.
Large changes were seen in V30Gy for the femoral heads of the
shifted plans. The reason for this phenomenon is owing to the very
small value of V30Gy for the femoral head in SSPT. In one case, V30Gy
was 0.02% in the nominal plan, and 0.31% in the shifted plan, so the
change was larger than 1500%. The V30Gy of SSPT was significantly
smaller than IMRT in both shifted and HU plans, so the results of
the dose to the femoral heads would not be changed by the effects
of treatment uncertainties.
A shortcoming of this study is that we have not evaluated the
functional part of the BM in the pelvic bone and assumed the
whole of the pelvic bone as active BM. Dinges et al. have used
nuclear imaging, (18)F-fluorothymidine positron emission tomog-
raphy, to specify the functional BM area in the pelvic bone [7].
The differences observed in this study may be somewhat altered
if we had used functional imaging, we feel that the difference
would not be large however.
Another limitation of this study is that we conducted the eval-
uation of the effects of anatomical changes by replacing the Houns-
field Unit of the bowel bag, not by using several CT scans taken
during the course of the treatment to evaluate the effects of inter-
fractional uncertainties due to bowel gas and anatomical changes
[37].
The study is also limited by possible biases in the assumptions
of the study. Among these the usefulness of NTCP and gEUD is still
debated. Also, the parameters proposed by Basan et al. have not yet
been validated in prospective clinical studies. The present study
suggests that SSPT could offer a new way ahead for WPRT com-
bined with chemotherapy, although whether SSPT actually does
reduce the incidence and/or severity of HT has to be confirmed
in clinical studies.5. Conclusions
Compared with IMRT, SSPT using SFO can achieve significant
reductions in the dose to BM with adequate dose coverage to the
PTV. The LKB-NTCP value for the HT3+ of SSPT is significantly
smaller than that of IMRT. These results indicate the advantage
of WPRT with SSPT using SFO considering the risk of severe HTand possibly to the femoral heads. However, for dose reductions
to the bowel, rectal tissue, and bladder adverse effects, SSPT using
SFO is inadequate.Acknowledgements
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